Navigation Links
Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
Date:10/10/2007

ignation from the U.S. Food and Drug Administration (FDA) and has been designated an orphan medicinal product by the European Medicines Agency (EMEA) for the treatment of Hodgkin's lymphoma.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical programs: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections; an HDAC program for Huntington's disease; a sirtuins program for cancer; and a beta-lactamase program to overcome antibiotic resistance. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements relating to the planned
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Idaho , Jan. 23, 2015  Now available for ... No. 7,849,611) support that prevents ankle sprains by cushioning ... brace, it fits securely around the outside of any ... mobility & comfort while still offering protection against sprains. ...
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), ... equipment for all forms of sports, including extreme motor ... brace, announced today that the UISP Lega Motociclismo Lombardia, ... all riders to wear a neck brace during its ...
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... N.J., May 26, 2011 Johnson & Johnson (NYSE: ... its Pharmaceuticals business at a meeting with the investment ... and pharmaceuticals segment will review how the business plans ... needs and outpace pharmaceutical market growth with an optimized ...
... Pharmaceuticals, Inc. (NASDAQ: AMLN ) ("Amylin" or "the ... the Southern District of California issued a temporary restraining order ... ) ("Lilly") relating to its litigation with respect to the ... District Court restrained Lilly from proceeding with its plans to ...
Cached Medicine Technology:Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 2Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 3Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 4Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 5Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 2Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 3Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 4
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... Researchers at the University of Wisconsin have reported that ... attack of shingles can now get,relief through a patch ... caused the varicella zoster virus, which also causes chicken ... one side of the body and,the pain can persist ...
... Danish researchers led by Annette Wind Olsen have reported ... for pregnancies that last,longer than 42 weeks or 294 ... pregnant mothers. The researchers conducted a study of about ... the group had a first,pregnancy that had lasted longer ...
... that would help improve patient safety by reducing medication errors. ... many as 7,000 deaths. These errors have been attributed to ... on prescriptions, or too many new drugs for doctors to ... study reported// between 45,000 and 98,000 death due to medical ...
... issue of the journal Alcoholism: Clinical and Experimental Research ... smell. Researchers from the University Clinics of Innsbruck studied ... healthy people who were matched for age, gender and ... devices that dispense odour, to test each nostril at ...
... Interstitial cystitis is a chronic, painful inflammatory condition of ... women , but can also affect men. Investigators are ... was found to be effective in treating interstitial cystitis, ... through a catheter. An earlier pilot study of BCG// ...
... Laboratories Chairman, Tajendra Khanna, in a recent seminar organised ... Reputation', spoke about the comapny's plan of foraying into ... would create stiff competition for the key player in ... market share. The company plans to market a few ...
Cached Medicine News:
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Coaxial fiberoptic headlight has fixed spot size of 120mm. It weighs only 4.5 ounces....
View Mex-2 is designed for out-patient surgery, hospital rounds and house calls....
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband....
Medicine Products: